-
Lexicon Prices 17.5M Shares At $2.25 per Share
Thursday, October 18, 2012 - 9:27am | 398Lexicon Pharmaceuticals (Nasdaq: LXRX) today announced the pricing of a public offering of its common stock in which the aggregate net proceeds to Lexicon will be approximately $37.2 million. The public offering consists of 17,500,000 shares of its common stock at a public offering price of $2.25...
-
Lexicon Announces Proposed Common Stock Offering
Wednesday, October 17, 2012 - 4:14pm | 320Lexicon Pharmaceuticals (NASDAQ: LXRX) today announced that it commenced an offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters...
-
Benzinga's Top Pre-Market Gainers
Tuesday, October 16, 2012 - 8:15am | 105Lexicon Pharmaceuticals (NASDAQ: LXRX) surged 7.84% to $2.75 in the pre-market session. Lexicon Pharmaceuticals' PEG ratio is 0.07. Mattel (NASDAQ: MAT) added 4.15% to $36.89 in the pre-market session. Mattel reported a 22% rise in its third-quarter net profit. Domino's Pizza (NYSE: DPZ) moved...
-
Benzinga's Top Pre-Market Gainers
Friday, October 12, 2012 - 8:15am | 123Beazer Homes USA (NYSE: BZH) surged 383.29% to $17.06 in the pre-market session. Beazer Homes announced a 1-for-5 reverse split of its common stock. STMicroelectronics NV (NYSE: STM) added 13.12% to $6.38 in the pre-market session. STMicroelectronics has a dividend yield of 6.10%. Lexicon...
-
A Peek Into The Market Before The Trading Starts
Friday, October 12, 2012 - 7:16am | 375Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 30 points to 13,295.00 and S&P 500 index futures rose 4.60 points to 1,433.00. Nasdaq 100 futures gained 4.75 points to 2,718.00. A Peek Into Global Markets European markets were...
-
Lexicon Pharmaceuticals Announces Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
Friday, October 12, 2012 - 6:30am | 197Lexicon Pharmaceuticals (NASDAQ: LXRX) announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego,...
-
Neurocrine Announces Start of Phase 2B Study of Vmat2 Inhibitor
Monday, October 1, 2012 - 4:06pm | 72Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-...
-
Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Thursday, August 16, 2012 - 6:07am | 471Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101. The Phase 1 study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, was a dose...
-
Maxygen Says No Plans to Interdependently Continue Further Development; Continues to Evaluate Strategic Options; Evaluating Merger for Company
Tuesday, August 7, 2012 - 4:15pm | 75Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced financial and business results for the quarter ended June 30, 2012. Maxygen also announced today that its Board of Directors has authorized a special pro rata distribution of $3.60 per share for each outstanding share of Maxygen...
-
Benzinga's Top Pre-Market Gainers
Monday, August 6, 2012 - 8:09am | 118Lexicon Pharmaceuticals (NASDAQ: LXRX) added 10.62% to $2.50 in the pre-market session. Lexicon Pharmaceuticals' PEG ratio is 0.06. Cognizant Technology Solutions (NASDAQ: CTSH) soared 7.10% to $61.97 in the pre-market trading. Cognizant Technology Solutions reported a rise in its second-quarter...
-
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
Tuesday, July 31, 2012 - 6:37am | 525Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today updated its drug development progress and reported financial results for the three and six months ended June 30, 2012. "Our positive top-line results from the Phase 2b study of LX4211 mark a very important milestone in the advancement of Lexicon's...
-
Metabolix Signs Letter of Intent with Antibióticos for Production of Mirel Biopolymer Resin
Thursday, July 26, 2012 - 4:12pm | 121Metabolix, Inc. (NASDAQ: MBLX) today announced that it has signed a letter of intent with Antibióticos S.A. for production of MirelTM biopolymer resin at its manufacturing facility in Leon, Spain. Under the terms of the LOI, Metabolix will begin work immediately with Antibióticos to conduct a...
-
Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection
Wednesday, July 25, 2012 - 7:16am | 104Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (NYSE: GSK) has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta® to treat thrombocytopenia in adult patients with chronic...
-
Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene
Thursday, July 19, 2012 - 9:03am | 241Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Pfizer (NYSE: PFE) announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a...
-
A Peek Into The Market Before The Trading Starts
Friday, June 29, 2012 - 7:21am | 355Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 133 points to 12,659.00 and S&P 500 index futures rose 17.90 points to 1,340.30. Nasdaq 100 futures jumped 34.25 points to 2,562.00. A Peek Into Global Markets European markets were...